Owl Labs Earns Microsoft Teams Certification, Unveils Enhancements to Further Meet IT Needs for Enterprise Businesses & Government
Owl Labs, a global leader in 360-degree video conferencing solutions powering both smart standalone and connected products through patented software, today announced Microsoft Teams certified products, along with TAA compliant SKUs, and an expanded suite of IT solutions that build upon its superior meeting room offerings. The company's Meeting Owl 3 and Owl Bar products are now peripherals that are certified for Microsoft Teams, and the Meeting Owl 4+ is currently in the certification process, reaffirming Owl Labs’ alignment with Microsoft's trusted standards for quality and performance. In tandem, Owl Labs will be rolling out software and hardware enhancements to deliver even smoother integration of its industry-leading hybrid collaboration solutions that cater to businesses of all sizes.
"We've been delivering innovative hybrid meeting room solutions to companies since 2016. Today's announcement marks an exciting evolution as we expand our solutions to include enterprise-grade features starting with certifications to support IT teams at scale,” said Frank Weishaupt, CEO of Owl Labs. “We're giving enterprise IT buyers exactly what they've been asking for – powerful management tools, enhanced security, and seamless deployment options – all while preserving the intuitive experience our customers love."
Powered by patented AI-driven software, Owl Labs' devices continuously improve performance, supporting diverse scenarios from intimate discussions to large presentations. Designed for modern, distributed offices, Owl Labs products prioritise flexibility, portability, and affordability, fostering inclusive and collaborative environments for both remote and in-room participants.
Microsoft Teams Certification
With the certification of the Meeting Owl 3 and Owl Bar, and the Meeting Owl 4+ to follow, Owl Labs strengthens its position as a trusted partner for IT professionals in over 225,000 organisations, and 89 of the Fortune 100 companies. The Teams certification validates that Owl Labs products meet the rigorous requirements of IT buyers and ensures optimal functionality in enterprise ecosystems.
“The Microsoft Teams certification is a testament to our team's relentless pursuit of meeting customer and buyers’ needs,” said Frank Weishaupt, CEO of Owl Labs. “We've seen overwhelmingly positive results in the small and medium business market, which makes us optimistic about expanding to meet IT buyer needs in the enterprise segment. By meeting Microsoft's rigorous standards, we will continue to expand our capacity to foster seamless collaboration across organisations of all sizes.”
This certification underscores Owl Labs' dedication to delivering exceptional, plug-and-play devices that seamlessly integrate with Teams, offering flexible, scalable solutions that adapt to evolving IT and meeting space needs.
New Modes, Robust Analytics and Device Management
Owl Labs devices use robotics and patented AI-powered software to automatically switch between cameras to capture the best view of in-room attendees. Now, Owl Labs is enhancing its industry-leading products with additional Modes for the Meeting Owl product line, which include panorama and grid view, to allow people to better customise their view and have even more natural, face-to-face conversations that transcend physical distance.
To further provide secure and flexible collaboration for IT administrators, Owl Labs offers the Nest®, a customer analytics platform that serves as an additional customer admin portal to the Teams management tools, that gives visibility and control over your organisation's Owl Labs devices all in one place, for status updates and notifications, minimising the need for physical meeting room checks. Supporting bulk device management for scalability, the Nest is expanding its features to enhance meeting analytics and enable large-scale deployments, addressing the needs of both smaller fleets and larger enterprises.
TAA Compliance and Cyber Essentials Plus
Owl Labs’ products have also acquired additional certifications including Trade Agreement Act (TAA) Compliance, Cyber Essentials Plus certification and Bureau of Indian Standards (BIS) certification, addressing stringent security and compliance requirements for government and enterprise buyers, reinforcing the company’s commitment to trust and reliability.
Owl Labs software is developed in the U.S. by an experienced team of engineers who are continually iterating to make Owl products smarter over time. All software adheres to industry-standard security protocols and Owl devices connect via a private, dedicated wireless network.
To learn more about Owl Labs and its connected device system of video conferencing solutions for hybrid organisations, visit www.owllabs.com.
About Owl Labs:
Owl Labs is the first company to build AI-powered, 360-degree video conferencing solutions for hybrid organisations. Its connected device system and Owl Intelligence System™ software make meetings more inclusive and collaborative by levelling the playing field between remote and in-room participants. The Meeting Owl® 4+ is the latest generation of the first WiFi-enabled, 360-degree camera, microphone and speaker that automatically zooms in on whoever’s speaking. Owl Labs has raised $47 million in funding and is based in Boston, with remote and hybrid employees all over the world. To learn more and explore the company’s research on the State of Hybrid Work, visit OwlLabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250127135503/en/
Contacts
Moxie Communications Group | press@owllabs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)31.1.2025 08:00:00 EET | Press release
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025. Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule3,4,5.Previously announced data from the phase III READY clinical trial program demonstrated rapid onset as soon as Day 1 (reported by up to 39% of subjects) and long-lasting efficacy for 6 months (main
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain31.1.2025 01:25:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109747971/en/ JOURNAVX bottle and tablet (Photo: Business Wire) “Today’s approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With the approval of JOURNAVX, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we h
Chemelex Embarks on New Chapter as Independent Company, Appoints David Prystash as CEO30.1.2025 23:51:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announces two significant milestones in its history: the completion of its separation from nVent and the appointment of David Prystash as Chief Executive Officer. Following the acquisition by Brookfield Asset Management’s private equity business, Chemelex is now operating as an independent entity, positioned for accelerated growth and innovation in the thermal management sector. As a pioneer in self-regulating heat tracing and other technologies, Chemelex, formerly the Thermal Management business of nVent, has long been recognized as an expert within the industry. The company will build on this legacy, continuing its mission to deliver high-quality electric thermal and sensing solutions that protect critical processes, places, and people worldwide. Chemelex's "Excellence is Everything" approach underscores its commitment to innovation, reliability, and exceptional service for its diverse clientele, including ind
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom